GPT and digestive system disorder: Moreover, two patients in the 3.2 mg/m2 cohort in the dose-escalation stage discontinued treatment because of treatment-emergent adverse events (TEAEs) (gastrointestinal disorders and hepatotoxicity), while only 1 (4.5%) patient in the dose-expansion stage discontinued the treatment due to TEAEs (grade 4 ALT increased and grade 3 AST increased).